A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation (CARDIOVERT)
A Placebo-controlled, Parallel-group, Double Blind, Randomized, Multi-cohort Phase 2 Study to Investigate Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BAY 3670549 in Adult Participants With Atrial Fibrillation.
The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called electrical cardioversion.
Electrical cardioversion is a procedure that helps the heart return to a normal rhythm. In this study, each participant will get a single intravenous (IV) infusion of either BAY 3670549 or a placebo. Participants will then be observed to see whether the heart rhythm returns to a normal rhythm. If it does not, electrical cardioversion can still be performed as planned. The study will look at how many participants return from AF to a normal rhythm, without needing electrical cardioversion and how long it takes. It will also show how many participants experience medical problems after treatment and how BAY 3670549 move into, through and out of the participants' body.
The total duration of the study for an individual participant may be up two months.
The findings from this study may contribute to the development of a new treatment option for people with AF.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Bayer Clinical Trials Contact
- Telefoonnummer: 18888422937
- E-mail: clinical-trials-contact@bayer.com
Studie Locaties
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, België, 3000
- Werving
- UZ Leuven Gasthuisberg - Cardiology diseases department
-
-
Limburg
-
Hasselt, Limburg, België, 3500
- Nog niet aan het werven
- Jessa Ziekenhuis | Hartcentrum Hasselt
-
-
West Flanders
-
Roeselare, West Flanders, België, 8800
- Nog niet aan het werven
- AZ Delta | Clinical Trial Center - Cardiology
-
-
-
-
Plovdiv Province
-
Plovdiv, Plovdiv Province, Bulgarije, 4001
- Nog niet aan het werven
- University Multiprofile Hospital For Active Treatment Sveti Georgi' - EAD Department of Intensive Cardiology"
-
-
Sofia City Province
-
Sofia, Sofia City Province, Bulgarije, 1233
- Nog niet aan het werven
- Multiprofile Hospital for Active Treatment Knyaginya Klementina Sofia EAD | Cardiology Department
-
Sofia, Sofia City Province, Bulgarije, 1527
- Werving
- University Hospital for Active Treatment Tsaritsa Joanna - ISUL | Cardiology Clinic
-
-
Veliko Tarnovo Province
-
Veliko Tarnovo, Veliko Tarnovo Province, Bulgarije, 5000
- Werving
- Multiprofile Hospital for Active Treatment Dr. Stefan Cherkezov | Base 1 - Cardiology Department
-
-
-
-
Lower Saxony
-
Hanover, Lower Saxony, Duitsland, 30625
- Nog niet aan het werven
- Medizinische Hochschule Hannover|Kardiologie und Angiologie
-
-
North Rhine-Westphalia
-
Bad Oeynhausen, North Rhine-Westphalia, Duitsland, 32545
- Nog niet aan het werven
- Herz-und Diabeteszentrum NRW|Elektrophysiologie/Rhythmologie
-
-
Thuringia
-
Altenburg, Thuringia, Duitsland, 04600
- Werving
- Klinikum Altenburger Land GmbH-Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin
-
-
-
-
-
Budapest, Hongarije, 1122
- Werving
- Semmelweis Egyetem, Varosmajori Sziv- és Ergyogyaszati Klinika
-
-
Tolna County
-
Szekszárd, Tolna County, Hongarije, 7100
- Nog niet aan het werven
- Tolna Vármegyei Balassa János Kórház - I. Belgyógyászati Osztály: Kardiológia, Nefrológia
-
-
-
-
Apulia
-
Acquaviva delle Fonti, Apulia, Italië, 70021
- Werving
- Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC
-
-
Lazio
-
Rome, Lazio, Italië, 00161
- Nog niet aan het werven
- Azienda Ospedaliero-Universitaria Policlinico Umberto I - Malattie Cardiovascolari
-
-
Lombardy
-
Milan, Lombardy, Italië, 20138
- Werving
- Centro Cardiologico Monzino S.p.A. - UO Scompenso e Cardiologia Clinica
-
-
The Marches
-
Torrette, The Marches, Italië, 60126
- Nog niet aan het werven
- Azienda Ospedaliero Universitaria Delle Marche - Clinica di Cardiologia e Aritmologia
-
-
-
-
-
Groningen, Nederland, 9713 GZ
- Nog niet aan het werven
- Universitair Medisch Centrum Groningen
-
-
Limburg
-
Maastricht, Limburg, Nederland, 6229 HX
- Nog niet aan het werven
- Maastricht UMC
-
-
-
-
Lesser Poland Voivodeship
-
Chrzanów, Lesser Poland Voivodeship, Polen, 32-500
- Nog niet aan het werven
- American Heart of Poland S.A. - MCSN, PAKS w Chrzanowie - Oddział Intensywnej Opieki Kardiologicznej
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-090
- Nog niet aan het werven
- USK nr 4 w Lublinie - Kliniczny Odd. Kardiologii, Reh. Kardio., Ch. Wew. z Pododdzialem Intensywnej Opieki Kardio.
-
-
Masovian Voivodeship
-
Grodzisk Mazowiecki, Masovian Voivodeship, Polen, 05-825
- Werving
- Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. sw. Jana Pawla II
-
-
Silesian Voivodeship
-
Bielsko-Biala, Silesian Voivodeship, Polen, 43-316
- Nog niet aan het werven
- American Heart of Poland S.A. - PAKS Centrum Kardiologii i Kardiochirurgii w Bielsku-Białej - Oddział Kardiologii
-
-
-
-
California
-
San Francisco, California, Verenigde Staten, 94143
- Ingetrokken
- UCSF Advanced Heart Failure Comprehensive Care Center
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Nog niet aan het werven
- UCHealth University of Colorado Hospital - Cardiology
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Nog niet aan het werven
- Massachusetts General Hospital - Cardiology
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Werving
- Henry Ford Hospital - Cardiology
-
-
Minnesota
-
Maplewood, Minnesota, Verenigde Staten, 55109
- Ingetrokken
- M Health Fairview Heart Clinic - Maplewood
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27704
- Nog niet aan het werven
- Duke University Hospital - Cardiology
-
-
Texas
-
Fort Worth, Texas, Verenigde Staten, 76104
- Nog niet aan het werven
- Texas Health Heart and Vascular Specialists - Fort Worth
-
Tyler, Texas, Verenigde Staten, 75701
- Nog niet aan het werven
- CHRISTUS Trinity | Mother Frances Louis and Peaches Owen Heart Hospital - Electrophysiology Clinic
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Participant must be 18 to 85 years of age inclusive, at the time of signing the informed consent.
- Participant is hemodynamically stable and does not require emergency cardioversion, as determined by the investigator.
- Participant has a current episode of atrial fibrillation (AF) ongoing for at least 3 hours and no more than 30 days at the time of randomization.
- Participant has an indication for electrical cardioversion of AF, as determined by the investigator according to standard clinical practice and national/institutional guidelines.
- At randomization, successful initiation and achievement of therapeutic levels of anticoagulation therapy, as well as completion of imaging evaluation for left atrial thrombi, as appropriate for the duration of the AF episode and risk for the participant according to national guideline and institution-specific routine practice.
- BMI within range [18 - 39.9] kg/m2.
- Contraceptive use by participants or participant partners should be consistent with the study protocol and local regulations regarding the methods of contraception for those participating in clinical studies.
- Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
- Willing and able to comply with the receipt, home use, and return of the continuous ECG recording device, as well as with the participation in scheduled telephone follow-up assessments.
Exclusion Criteria:
-
Current atrial flutter (AFL) or combined AF/AFL
-
Contraindication for electrical cardioversion on planned treatment day
-
Documented severely dilated left atrium (left atrial diameter, LAD >5 cm) measured by any modality within the 6 months prior to screening; if several values are available, the most recent one shall be reported. If left atrium diameter was not measured in the last 6 months or a major cardiovascular event occurred within the last 6 months, a new measurement must be done at screening
-
Unsuccessful conversion of current AF episode (pharmacologically or electrically)
-
Known severe valvular heart disease (e.g., severe mitral regurgitation, severe aortic stenosis)
-
Patients with NYHA Class ≥ III heart failure, or with active management of acute heart failure decompensation on treatment day.
-
History within the preceding 3 months prior to randomization of any of the following events, or any other significant cardiovascular event as judged by the investigator:
- Stroke
- Myocardial infarction
- Unstable angina pectoris or other signs of myocardial ischemia
- Cardiac surgery
- Transcatheter valve replacement
- Percutaneous coronary intervention (PCI)
- Coronary artery bypass graft (CABG) or other revascularization procedure
-
Severe renal impairment, i.e., estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² (using CKD-EPI formula) or requiring dialysis
-
Severe hepatic impairment, i.e. Child Pugh Class C
-
Use of anti-arrhythmic class I or III drugs within 5 half-lives before study drug administration (oral amiodarone in the previous 3 months)
-
Hypertension with SBP ≥ 180 mmHg or hypotension (SBP < 90 mmHg) at randomization (based on the second BP measurement)
-
Stressor-associated AF, i.e., in the setting of an acute and reversible stressor (e.g., cardiac surgery, myocarditis, endocarditis, sepsis, pneumonia, etc.). This includes ablation procedure within the preceding one month prior to randomization.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
|
intravenous (IV) treatment |
|
Experimenteel: BAY 3670549
|
intravenous (IV) treatment |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants with conversion from atrial fibrillation (AF) to sinus rhythm (SR), sustained for ≥1 minute, within 3 hours after start of study intervention administration, and prior to use of rescue therapy or other SoC for cardioversion
Tijdsspanne: Up to 3 hours after start of administration of study intervention
|
AF = atrial fibrillation ; SR = sinus rhythm ; SoC = Standard of Care; |
Up to 3 hours after start of administration of study intervention
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants who experienced Treatment Emergent Adverse Events (TEAE)s
Tijdsspanne: From pre-dose* up to 48 hours after start of administration of study intervention
|
TEAE = Treatment Emergent Adverse Events; *Pre-dose: Within 4 hours prior to study intervention administration |
From pre-dose* up to 48 hours after start of administration of study intervention
|
|
Time to conversion from AF to SR as defined in the primary endpoint
Tijdsspanne: Up to 3 hours after start of administration of study intervention
|
AF = atrial fibrillation SR = sinus rhythm; |
Up to 3 hours after start of administration of study intervention
|
|
Number of Participants in SR, at 3 hours after start of study intervention administration without prior use of rescue therapy or other SoC for cardioversion
Tijdsspanne: Up to 3 hours after start of administration of study intervention
|
SoC = Standard of Care; |
Up to 3 hours after start of administration of study intervention
|
|
Plasma concentration of BAY 3670549 at the end of the infusion
Tijdsspanne: From pre-dose* up to 8 hours after start of administration of study intervention
|
*Pre-dose: Within 4 hours prior to study intervention administration |
From pre-dose* up to 8 hours after start of administration of study intervention
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 22961
- 2025-523807-31-00 (Ctis)
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .